Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | SRC | P12931 | 3/20 | 0.51 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.51 |
| ▸ | EPHA8 | P29322 | 1/20 | 0.51 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.51 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.51 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.51 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.51 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492471 | 1.00 | PDGFRB (0.55) | PDGFRBPDGFRAEGFRSRCBMPR1B | |
| Hydrochloric Acid SCHEMBL4463414 | 0.98 | PDGFRB (0.54) | PDGFRBPDGFRAEGFRSRCBMPR1B | |
| SCHEMBL30498652 | 0.91 | EGFR (0.47) | PDGFRBPDGFRAEGFRSRCBMPR1B | |
| SCHEMBL23597420 | 0.91 | EGFR (0.47) | PDGFRBPDGFRAEGFRSRCBMPR1B | |
| SCHEMBL28439891 | 0.91 | EGFR (0.47) | PDGFRBPDGFRAEGFRSRCBMPR1B | |
| SCHEMBL21753968 | 0.89 | PDGFRB (0.47) | PDGFRBPDGFRAEGFRSRCBMPR1B | |
| SCHEMBL17211117 | 0.89 | PDGFRB (0.47) | PDGFRBPDGFRAEGFRSRCBMPR1B | |
| SCHEMBL20032547 | 0.88 | SRC (0.46) | PDGFRBPDGFRAEGFRSRCBMPR1B | |
| SCHEMBL23456874 | 0.88 | PDGFRB (0.46) | PDGFRBPDGFRAEGFRSRCBMPR1B | |
| SCHEMBL14310926 | 0.87 | EHMT2 (0.49) | PDGFRBPDGFRAEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 649 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262200-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | EXELIXIS INC (US) | 2025-08-21 | — | — | US | claimed |
| US-20250017916-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS INC (US) | 2025-01-16 | — | — | US | claimed |
| US-12128039-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2024-10-29 | — | — | US | claimed |
| US-20240189298-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | EXELIXIS, INC. | 2024-06-13 | — | — | US | claimed |
| WO-2023222946-A1 | PROCESS FOR THE PREPARATION OF CABOZANTINIB | FERMION OY (FI) | 2023-11-23 | — | — | WO | claimed |
| EP-4019498-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | Exelixis, Inc. (US) | 2022-06-29 | — | — | EP | claimed |
| US-20220175757-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2022-06-09 | — | — | US | claimed |
| US-11298349-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2022-04-12 | — | — | US | claimed |
| US-20220023284-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2022-01-27 | — | — | US | claimed |
| CN-112920181-A | N- (5-phenyl-1, 3, 4-thiadiazole-2-yl) benzamide compound | 中国医科大学 | 2021-06-08 | — | — | CN | claimed |
| CN-110240563-A | A kind of rich preparation method for Buddhist nun of card | 南京法恩化学有限公司 | 2019-09-17 | — | — | CN | claimed |
| US-20190030021-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2019-01-31 | — | — | US | claimed |
| US-9717720-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | EXELIXIS, INC. (US) | 2017-08-01 | — | — | US | claimed |
| US-20170057921-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. | 2017-03-02 | — | — | US | claimed |
| CN-106008336-A | Preparation method of 4-chloro-6, 7-dimethoxyquinoline | 上海工程技术大学 | 2016-10-12 | — | — | CN | claimed |
| CN-105111141-A | Cabozantinib intermediate 4-hydroxy-6,7-dimethoxyquinoline and preparation method thereof | SUZHOU MOER PHARMACEUTICAL CO LTD | 2015-12-02 | — | — | CN | claimed |
| US-20140200242-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | EXELIXIS, INC. (US) | 2014-07-17 | — | — | US | claimed |
| CN-103664778-A | Synthesis method of antineoplastic drug cabozant inib | SUZHOU MOLE PHARMACEUTICAL CO LTD | 2014-03-26 | — | — | CN | claimed |
| EP-2673262-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | Exelixis, Inc. (US) | 2013-12-18 | — | — | EP | claimed |
| WO-2012109510-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | EXELIXIS, INC. (US) | 2012-08-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200242-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDGFRB 3177/4885PDGFRA 3965/4885EGFR 4046/4885 |
| US-20170057921-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, HRH2 | PDGFRB 3455/4885PDGFRA 3972/4885EGFR 3998/4885 |
| US-20240189298-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDGFRB 3177/4885PDGFRA 3965/4885EGFR 4046/4885 |
| US-20190030021-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, HRH2 | PDGFRB 3455/4885PDGFRA 3972/4885EGFR 3998/4885 |
| US-11298349-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDGFRB 3177/4885PDGFRA 3965/4885EGFR 4046/4885 |
| US-20250262200-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | HAX1, HRH2, HRH1 | PDGFRB 3867/4885PDGFRA 4279/4885EGFR 3934/4885 |
| US-20250017916-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDGFRB 3177/4885PDGFRA 3965/4885EGFR 4046/4885 |
| US-20220175757-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDGFRB 3177/4885PDGFRA 3965/4885EGFR 4046/4885 |
| US-20220023284-A1 | Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDGFRB 3177/4885PDGFRA 3965/4885EGFR 4046/4885 |
| US-12128039-B2 | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDGFRB 3177/4885PDGFRA 3965/4885EGFR 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.